Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
MUC20 Biologics Sequence Review Report 2026: Mucin-20 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MUC20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MUC13 Biologics Sequence Review Report 2026: Mucin-13 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MUC13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MUC1 Biologics Sequence Review Report 2026: Mucin-1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MUC1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MST1R Biologics Sequence Review Report 2026: Macrophage-stimulating protein receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MST1R sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MS4A18 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 18 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A18 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MS4A15 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 15 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MS4A14 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 14 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MS4A13 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 13 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MS4A12 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 12 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MS4A10 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 10 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MS4A8 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 8 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MS4A7 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.